PBYI
PUMA BIOTECHNOLOGY, INC.
NASDAQ · Healthcare · Biotechnology · US
$10.54
−0.75%Oct 22, 2026, 20:11 UTC
PUMA BIOTECHNOLOGY, INC. announced that it will issue its third-quarter 2026 financial results after the market close on November 5, 2026.
Source:Sep 17, 2026, 20:07 UTC
Puma Biotechnology initiated ALISCA-Lung2, a Phase II trial of alisertib in combination with paclitaxel for patients with advanced small cell lung cancer.
Source:Aug 7, 2026, 00:13 UTC
Puma Biotech reported Q2 2026 earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share, and compared to $0.15 per share a year ago.